The lawsuit contends that Park Ha Biological Technology failed to disclose a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals to inflate share prices. According to the filing, the company’s IPO was allegedly structured with an intentionally low public float specifically designed to facilitate this manipulation. These undisclosed factors, combined with artificial trading activity, rendered the firm's public statements regarding its prospects and risk profile materially misleading.

Investors seeking to serve as lead plaintiff in this litigation must move the court by September 28, 2026. Participation in the lawsuit does not require out-of-pocket fees, as the firm operates on a contingency fee basis. While no class has been certified yet, affected shareholders may choose to retain their own counsel or remain as absent class members. Those interested in the proceedings can contact Phillip Kim at the Rosen Law Firm for further information.